Niche Expertise in Phase I/IIa and an Individual Approach Contribute to a Unique Experience
For more than 14 years, LCG Bioscience has developed experience in a wide range of exploratory phase clinical development studies, often requiring complex clinical procedures, special populations, or surrogate pharmacodynamic endpoints.
We have successfully performed over 350 exploratory phase clinical development studies:
| First administration into human | Early efficacy in healthy volunteers |
| Human ADME studies | Proof-of-concept studies |
| Drug-drug, food and oral contraceptive interaction studies | Bioavailability and bioequivalence |
In every area we are contributing to the development of important therapies. It’s that belief which motivates our staff. More than 70 clinical research professionals work for LCG including experienced physicians, scientists, research nurses and regulatory QPs.
We work together as an enthusiastic, motivated and service-orientated team, where honest communication is key.
LCG Bioscience operates in accordance with the principles of ICH Good Clinical Practice 1996, EU Directive 2001/20/EC and EU Directive 2005/28/EC and has been successfully inspected by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for GCP and GMP.
LCG Bioscience is an Investor In People employer.